Using engineered tRNA to treat hereditary eye diseases
Anticodon Engineered tRNA for the Treatment of Hereditary Eye Disease
['FUNDING_R21'] · UNIVERSITY OF IOWA · NIH-11035731
This study is looking at a new way to help people with hereditary eye diseases caused by genetic mutations that stop protein production too early, using a special type of tRNA in mice to see if it can help restore the function of eye cells and possibly lead to new treatments.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF IOWA (nih funded) |
| Locations | 1 site (IOWA CITY, UNITED STATES) |
| Trial ID | NIH-11035731 on ClinicalTrials.gov |
What this research studies
This research investigates the use of anticodon engineered tRNA (ACE-tRNA) to address hereditary eye diseases caused by premature termination codons (PTCs) in genetic sequences. By utilizing a specially designed strain of transgenic mice, the study aims to evaluate the effectiveness and safety of ACE-tRNA in promoting the translation of proteins that are otherwise prematurely stopped due to genetic mutations. The approach focuses on assessing how well this modified tRNA can rescue the function of ocular cells affected by these mutations, potentially leading to new treatment options for various eye conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with hereditary eye diseases linked to nonsense mutations, such as retinal disease, glaucoma, or congenital cataracts.
Not a fit: Patients with hereditary eye diseases not caused by premature termination codons or those with other unrelated ocular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel therapeutic approach for patients suffering from hereditary eye diseases, potentially restoring vision or preventing further degeneration.
How similar studies have performed: Previous research has shown promise in using modified tRNA approaches for similar genetic conditions, indicating potential for success in this novel application.
Where this research is happening
IOWA CITY, UNITED STATES
- UNIVERSITY OF IOWA — IOWA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ANDERSON, MICHAEL G — UNIVERSITY OF IOWA
- Study coordinator: ANDERSON, MICHAEL G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.